2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04840823 (ClinicalTrials.gov) | March 26, 2021 | 29/3/2021 | Enoxacin for Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-blind, Parallel Group, Single Centre, Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Orally Administered Doses of Enoxacin (200mg Twice Daily, 400mg Twice Daily and 600mg Twice Daily) in Adults With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Enoxacin;Drug: Placebo | McGill University | Weizmann Institute of Science;Apotex Inc. | Recruiting | 18 Years | 85 Years | All | 36 | Phase 1/Phase 2 | Canada |